

UNITED STAT. DEPARTMENT OF COMMERCE Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

09/0038(0 APPLICATION NUMBER FIRST NAMED APPLICANT ATTY: DOCKET NO. 09/003,810 01/07/98 RAMAKRISHNAN-٧ 44481-5017-0 EXAMINER 009629 HM12/1222 MORGAN, LEWIS & BOCKIUS 1800 M STREET NW WASHINGTON DC 20036-5869 SAMEL, F PAPER NUMBER 11 1644 DATE MAILED: 12/22/99

This is a communication from the examiner in charge of your application.

	COMMISSIONER OF PATENTS AND TRADEMARKS	
	OFFICE ACTION SUMMARY	
. 🗆	Responsive to communication(s) filed on 4/15/98 9/17/99	
	This action is FINAL.	
	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 D.C. 11; 453 O.G. 213.	
wh the	chortened statutory period for response to this action is set to expire month(s), or thirty days, ichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 36(a).	
Disposition of Claims		
· 🖂	Claim(s) 17-22 is/are pending in the application. Of the above, claim(s) is/are withdrawn from consideration.	
_	Of the above, claim(s)is/are withdrawn from consideration.	
	Claim(s) is/are allowed.	
님	Claim(s)is/are rejected.	
닏	Claim(s) is/are objected to. Claim(s) are subject to restriction or election requirement.	
Application Papers		
	See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948. The drawing(s) filed onis/are objected to by the Examiner. The proposed drawing correction, filed onisapproved disapproved. The specification is objected to by the Examiner. The oath or declaration is objected to by the Examiner.	
Priority under 35 U.S.C. § 119		
	Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).	
	All Some* None of the CERTIFIED copies of the priority documents have been	
,	received. received in Application No. (Series Code/Serial Number) received in this national stage application from the International Bureau (PCT Rule 17.2(a)).	
,	Certified copies not received:	
	Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e).	
Atta	achment(s)	
	Notice of Reference Cited, PTO-892	
	Information Disclosure Statement(s), PTO-1449, Paper No(s).	
	Interview Summary, PTO-413	
	Notice of Draftperson's Patent Drawing Review, PTO-948	
Ш	Notice of Informal Patent Application, PTO-152	
	-SEE OFFICE ACTION ON THE FOLLOWING PAGES-	

Serial No. 09/003810 Art Unit 1644

DETAILED ACTION

- 1. The location of your application in the PTO has changed. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Art Unit 1644, Group 1640, Technology Center 1600.
- 2. Please Note: In an effort to enhance communication with our customers and reduce processing time, Group 1640 is running a Fax Response Pilot for Written Restriction Requirements. A dedicated Fax machine is in place to receive your responses. The Fax number is 703-305-3704. A Fax cover sheet is attached to this Office Action for your convenience. We encourage your participation in this Pilot program. If you have any questions or suggestions please contact Paula Hutzell, Ph.D., Supervisory Patent Examiner at Paula. Hutzell@uspto.gov or 703-308-4310. Thank you in advance for allowing us to enhance our customer service. Please limit the use of this dedicated Fax number to responses to Written Restrictions.
- 3. This application contains claims directed to the following patentably distinct species of the claimed Invention: wherein the PDGF-mediated disease is:
 - A) restenosis,
 - B) vascular proliferative phenomenon and fibrosis,
 - C) prevention of vascular narrowings in vein grafts,
- D) prevention of vascular narrowings due to accelerated smooth muscle cell migration and proliferation in transplanted organs or
 - E) nonvascular fibrotic processes

These species are distinct because the pathological conditions differ in etiologies and therapeutic endpoints.

Applicant is required under 35 U.S.C. § 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claim 17 is generic, for example.

4. Applicant is advised that a response to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 C.F.R. § 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. M.P.E.P. § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. § 103 of the other invention.

Serial No. 09/003810 Art Unit 1644

- 5. Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed.
- 6. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. § 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 C.F.R. § 1.48(b) and by the fee required under 37 C.F.R. § 1.17(h).
- 7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Phillip Gambel whose telephone number is (703) 308-3997. The examiner can normally be reached Monday through Thursday from 7:30 am to 6:00 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (703) 308-3973. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center 1600 receptionist whose telephone number is (703) 308-0196.

Papers related to this application may be submitted to Technology Center 1600 by facsimile transmission. Papers should be faxed to Technology Center 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Fax Center telephone number is (703) 305-3014.

Phillip Gambel, PhD.
Patent Examiner
Technology Center 1600
December 20, 1999
THUMESUM



RESTRICTION ELECTION **FACSIMILE TRANSMISSION**

DATE:
FROM/ATTORNEY:
FIRM:
PAGES, INCLUDING COVERSHEET:
PHONE NUMBER:
TO EXAMINER:
ART UNIT:
SERIAL NUMBER:
FAX/TELECOPIER NUMBER: (703) 305-3704
PLEASE NOTE: THIS FACSIMILE NUMBER IS TO BE USED ONLY FOR RESPONSES TO RESTRICTIONS.
COMMENTS:
IF YOU HAVE NOT RECEIVED ALL THE PAGES OF THIS TRANSMISSION, PLEASE CONTACT THE ATTORNEY AT THE

TELEPHONE NUMBER LISTED ABOVE.

IN COMPLIANCE WITH 1096 OG 30, THE FILING DATE ACCORDED EACH OFFICIAL FAX TRANSMISSION WILL BE DETERMINED BY THE FAX MACHINE DATE STAMP FOUND ON THE LAST PAGE OF THE TRANSMISSION, UNLESS THAT DATE IS A SATURDAY, SUNDAY, OR FEDERAL HOLIDAY WITHIN THE DISTRICT OF COLUMBIA, IN WHICH CASE THE OFFICIAL DATE OF RECEIPT WILL BE THE NEXT BUSINESS DAY.

THE DOCUMENT(S) ACCOMPANYING THIS FACSIMILE TRANSMISSION CONTAIN(S) INFORMATION FROM THE UNITED STATES PATENT AND TRADEMARK OFFICE WHICH IS CONFIDENTIAL AND/OR LEGALLY PRIVILEGED. THIS INFORMATION IS FOR THE USE OF THE INDIVIDUAL OR FIRM NAMED ON THIS SHEET. IF YOU ARE NOT THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISCLOSURE, COPYING, DISTRIBUTION, OR THE TAKING OF ANY ACTION IN RELIANCE ON THE CONTENTS OF THIS INFORMATION IS STRICTLY PROHIBITED. THE DOCUMENTS SHOULD BE RETURNED TO THE PATENT AND TRADEMARK OFFICE IMMEDIATELY. IF THIS FACSIMILE IS RECEIVED IN ERROR, PLEASE NOTIFY THE ATTORNEY LISTED HEREON IMMEDIATELY.